Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares soared to an all-time high this week, reaching a peak of $24.44. According ...

CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently disclosed in an 8-K filing with the Securities and Exchange Commission on January 13, 2025, that the company has posted a corporate presentation ...

Swiss biotech Santhera Pharmaceuticals has started launch preparations for its Duchenne muscular dystrophy (DMD) drug Agamree (vamorolone) in the UK, following a recommendation from England’s price ...

US health systems and Regeneron Genetics Center launch the Truveta Genome Project, a $320M initiative to sequence up to 10M exomes. Focused on diversity, the project aims to link genetic data with ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch ...

(SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently ...

Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland - January 15 ...

Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, announces that the Scottish Medicines Consortium (SMC) has published recommendations that Agamree (vamorolone) is accepted for use ...

(RTTNews) - Santhera Pharmaceuticals said that it received positive recommendation from the Scottish Medicines Consortium for use of AGAMREE (Vamorolone) within NHS Scotland for the treatment of ...